Thomas Ahmadifar

May 17, 2023 | jdsupra.com | Thomas Ahmadifar |Valerie Dahiya |Shekida A. Smith-Sandy

The U.S. Securities and Exchange Commission (the SEC or the Commission) voted on Friday, April 14, 2023, to reopen the comment period for previously proposed amendments to Rule 3b-16 under the Exchange Act of 1934 (the Exchange Act).[1] Rule 3b-16 defines “exchange” as used in Section 3(a)(1) of the Exchange Act.[2] If adopted, the proposed amendments would expand the definition of “exchange” to capture a broader scope of trading platforms.

May 1, 2023 | jdsupra.com | Thomas Ahmadifar |Valerie Dahiya |Shekida A. Smith-Sandy

A new development has emerged in the series of changes to the regulation of finders (i.e., persons that receive compensation for making an introduction leading to a securities transaction) and mergers and acquisition brokers (M&A Brokers).

Mar 15, 2023 | jdsupra.com | Thomas Ahmadifar |Valerie Dahiya |Shekida A. Smith-Sandy

On March 10, 2023, volatility resulting from concerns regarding runs on certain banks triggered trading halts in those banks’ stocks on the New York Stock Exchange (NYSE) and Nasdaq. March 13, 2023, saw additional trading halts on bank stocks. This post provides a brief explanation of the Limit Up Limit Down (LULD) rules that pause and prevent trading in a single security from taking place outside a specific range, either up or down, from the average trading price during the previous five minutes.

Mar 10, 2023 | jdsupra.com | Thomas Ahmadifar |Valerie Dahiya

On March 1, 2023, the U.S. Department of Justice (DOJ) unsealed an indictment against the CEO of a publicly traded healthcare company (the Executive) relating to charges of an insider trading scheme. The indictment represents the first time the DOJ has brought criminal insider trading charges stemming from an executive’s use of a Rule 10b5-1 trading plan. The investigation is part of a data-driven initiative led by the DOJ’s Fraud Section to identify executive abuses of 10b5-1 trading plans.

Mar 8, 2023 | lexblog.com | Val Dahiya |Thomas Ahmadifar

On March 1, 2023, the U.S. Department of Justice (DOJ) unsealed an indictment against the CEO of a publicly traded healthcare company (the Executive) relating to charges of an insider trading scheme. The indictment represents the first time the DOJ has brought criminal insider trading charges stemming from an executive’s use of a Rule 10b5-1 trading plan. The investigation is part of a data-driven initiative led by the DOJ’s Fraud Section to identify executive abuses of 10b5-1 trading plans.